Nestin expression throughout multistep pathogenesis of multiple myeloma

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Nestin (NES) is a known stem cell marker, typically downregulated upon cell differentiation.
• NES can be re-expressed in injured tissues and cancers.
• Recent findings identified NES as a tumor-specific marker for plasma cells (PCs) in multiple myeloma (MM).

Purpose of the Study:

• To investigate Nestin (NES) expression across the spectrum of multiple myeloma (MM) developmental stages.
• To evaluate NES as a diagnostic and prognostic marker in MM.
• To explore the association of NES with clinical parameters and therapeutic response in MM.

Main Methods:

• Analysis of NES expression in bone marrow plasma cells (PCs) from 163 MM patients, 4 PCL patients, 9 MGUS patients, and 10 healthy controls.
• NES expression was also assessed in 6 MM cell lines.
• Methods included flow cytometry, real-time polymerase chain reaction, and immunochemistry.

Main Results:

• NES expression showed a trend of increase correlating with disease progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) and plasma cell leukemia (PCL).
• NES served as a reliable marker to differentiate MM patients from controls.
• High NES levels were significantly associated with the 1q21 gain genetic abnormality and predicted a worse response to conventional and novel therapies.

Conclusions:

• Nestin (NES) expression increases with multiple myeloma (MM) progression.
• NES is a valuable marker for distinguishing MM patients and predicting treatment outcomes.
• NES may play a significant role in MM pathogenesis and could become a useful clinical parameter.